苄基4-[(氯磺酰基)甲基]哌啶-1-羧酸 | 1211587-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苄基4-[(氯磺酰基)甲基]哌啶-1-羧酸
• 英文名称: benzyl 4-[(chlorosulfonyl)methyl]piperidine-1-carboxylate
• 英文别名: Benzyl 4-((chlorosulfonyl)methyl)piperidine-1-carboxylate；benzyl 4-(chlorosulfonylmethyl)piperidine-1-carboxylate
• CAS: 1211587-42-6
• 化学式: C₁₄H₁₈ClNO₄S
• mdl: MFCD18089412
• 分子量: 331.82
• InChiKey: JOQRDARBUIIJCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苄基4-[(氯磺酰基)甲基]哌啶-1-羧酸 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 H-4PiMS-Phe-NHiPr
  参考文献：
  名称：

  Conformational behavior of peptides containing residues of 3-azetidinesulfonic (3AzeS) and 4-piperidinemethanesulfonic (4PiMS) acids

  摘要：

  The conformational behavior of four model peptides containing residues of 3-azetidinesulfonic (3AzeS) and 4-piperidinemethane sulfonic (4PiMS) acids was studied in both a crystalline state and in solution using X-ray, NMR, and IR experiments. It was found that in the crystalline state, both of the models di- and tripeptides studied adopted extended conformations and demonstrated considerable conformational flexibility. In solution, it is likely that a flexible ensemble of conformations is adopted, including extended structures and more compact ones without persistent hydrogen bonds. One of the most interesting features of the peptides was the axial chirality observed due to the slow rotation around the amide bond formed by the endocyclic nitrogen atoms of the non-chiral 3AzeS and 4PiMS residues. It was shown for one of the derivatives that the configuration of the chiral axis had an impact on the conformation of the neighboring amino acid residue. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2013.12.001
• 作为产物：
  描述：

  1-Cbz-4-MS-甲基-哌啶 在 水 、 氯 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 苄基4-[(氯磺酰基)甲基]哌啶-1-羧酸
  参考文献：
  名称：

  构象受限的饱和杂环磺酰氯库

  摘要：

  描述了合成构象受限的饱和杂环磺酰氯的方法。遵循面向多样性的构象限制原则，设计并合成了一个饱和杂环磺酰氯的小型文库。该文库由九种成员组成，它们是氮杂环丁烷，吡咯烷和哌啶的衍生物。这些化合物从相应的Cbz保护的氨基醇开始，以克数计以19-88％的总收率制备。 磺酰氯-氮杂环-分子刚性-库-构象限制

  DOI：

  10.1055/s-0030-1260223

文献信息

• [EN] SUBSTITUTED PIPERIDINE COMPOUNDS<br/>[FR] COMPOSÉS PIPÉRIDINES SUBSTITUÉS
  申请人：EPIZYME INC

  公开号：WO2016040515A1

  公开（公告）日：2016-03-17

  The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供具有式（I）的取代哌啶化合物，以及其药学上可接受的盐和溶剂化合物，其中R1、B、X和Z如规范中所述。本公开还涉及使用式I的化合物治疗对SMYD蛋白质的阻断具有响应的疾病，如SMYD3或SMYD2。本公开的化合物特别适用于治疗癌症。
• ＳＭＹＤ 억제제
  申请人：Epizyme, Inc. 에피자임, 인코포레이티드(520130181594)

  公开号：KR20170045749A

  公开（公告）日：2017-04-27

  본 발명은 하기 화학식 I을 갖는 카복사미드 및 설폰아미드, 및 이의 약제학적으로 허용되는 염 및 용매화물을 제공한다. 본 발명은 또한, SMYD 단백질, 예를 들어, SMYD3 또는 SMYD2의 차단에 반응을 보이는 장애를 치료하기 위한 화학식 I의 화합물의 용도에 관한 것이다. 본 발명의 화합물은 암을 치료하는데 특히 유용하다: [화학식 I] 상기 식에서, A, Y, B, X, 및 Z는 명세서에 기술된 바와 같이 정의된다.

  本发明提供了具有以下化学式I的卡波萨米德和磺酰胺，以及其药学上可接受的盐和溶剂化合物。本发明还涉及化学式I化合物的用途，用于治疗对SMYD蛋白产生反应的障碍，例如SMYD3或SMYD2的阻断。本发明的化合物在治疗癌症方面特别有用：[化学式I] 在上述公式中，A、Y、B、X和Z如所述规范中所定义。
• SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS
  申请人：VANDERBILT UNIVERSITY

  公开号：US20150336925A1

  公开（公告）日：2015-11-26

  The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

  本发明提供了一种抑制抗凋亡Bcl-2家族成员髓系细胞白血病-1（Mcl-1）蛋白活性的化合物。本发明还提供了制药组合物以及使用化合物治疗因Mcl-1蛋白过度表达或失调而表现出的疾病和症状（例如癌症）的方法。
• Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
  申请人：VANDERBILT UNIVERSITY

  公开号：US10093640B2

  公开（公告）日：2018-10-09

  The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

  本发明提供了抑制抗凋亡 Bcl-2 家族成员骨髓细胞白血病-1（Mcl-1）蛋白活性的化合物。本发明还提供了药物组合物以及使用化合物治疗以 Mcl-1 蛋白过度表达或失调为特征的疾病和病症（如癌症）的方法。
• Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
  申请人：EPIZYME, INC.

  公开号：US10266526B2

  公开（公告）日：2019-04-23

  The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供了具有式（I）的羧酰胺类和磺酰胺类化合物：及其药学上可接受的盐和溶剂，其中A、Y、B、X和Z的定义如说明书所述。本公开还涉及使用式（I）化合物治疗对 SMYD 蛋白如 SMYD3 或 SMYD2 的阻断有反应的紊乱。本公开的化合物尤其适用于治疗癌症。